160 related articles for article (PubMed ID: 37720939)
21. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
[TBL] [Abstract][Full Text] [Related]
22. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
23. Adenocarcinoma of the esophagus and esophagogastric junction in patients older than 70 years: results of neoadjuvant radiochemotherapy followed by transthoracic esophagectomy.
Camerlo A; D'Journo XB; Ouattara M; Trousse D; Doddoli C; Thomas PA
J Visc Surg; 2012 Jun; 149(3):e203-10. PubMed ID: 22633088
[TBL] [Abstract][Full Text] [Related]
24. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation.
Coker AM; Barajas-Gamboa JS; Cheverie J; Jacobsen GR; Sandler BJ; Talamini MA; Bouvet M; Horgan S
J Laparoendosc Adv Surg Tech A; 2014 Feb; 24(2):89-94. PubMed ID: 24401141
[TBL] [Abstract][Full Text] [Related]
26. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing.
Abate E; DeMeester SR; Zehetner J; Oezcelik A; Ayazi S; Costales J; Banki F; Lipham JC; Hagen JA; DeMeester TR
J Am Coll Surg; 2010 Apr; 210(4):428-35. PubMed ID: 20347734
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
28. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
[TBL] [Abstract][Full Text] [Related]
29. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy.
Makary MA; Kiernan PD; Sheridan MJ; Tonnesen G; Hetrick V; Vaughan B; Graling P; Elster E
Am Surg; 2003 Aug; 69(8):693-700; discussion 700-2. PubMed ID: 12953828
[TBL] [Abstract][Full Text] [Related]
30. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis.
Plum PS; Damanakis A; Buschmann L; Ernst A; Datta RR; Schiffmann LM; Zander T; Fuchs H; Chon SH; Alakus H; Schröder W; Hölscher AH; Bruns CJ; Bludau M
J Cancer Res Clin Oncol; 2022 May; 148(5):1223-1234. PubMed ID: 34223965
[TBL] [Abstract][Full Text] [Related]
31. [Effects of robotic and laparoscopic-assisted surgery on lymph node dissection and short-term outcomes in patients with Siewert II adenocarcinoma of esophagogastric junction].
Wang D; Cao S; Tan X; Liu S; Liu X; Niu Z; Chen D; Wang D; Zhang J; Lv L; Li Y; Jiang H; Guo D; Li Y; Li Z; Zhou Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):156-163. PubMed ID: 30799538
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus.
Leers JM; DeMeester SR; Chan N; Ayazi S; Oezcelik A; Abate E; Banki F; Lipham JC; Hagen JA; DeMeester TR
J Thorac Cardiovasc Surg; 2009 Sep; 138(3):594-602; discussion 601-2. PubMed ID: 19698841
[TBL] [Abstract][Full Text] [Related]
33. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
Kuhnle PJ; Israel KF; Menges M
Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
[TBL] [Abstract][Full Text] [Related]
34. Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-volume Center Retrospective Cohort Analysis.
Wirsik NM; Schmidt T; Nienhüser H; Donlon NE; de Jongh C; Uzun E; Fuchs HF; Brunner S; Alakus H; Hölscher AH; Grimminger P; Schneider M; Reynolds JV; van Hillegersberg R; Bruns CJ
Ann Surg; 2023 Nov; 278(5):683-691. PubMed ID: 37522845
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
36. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease.
Stiles BM; Mirza F; Coppolino A; Port JL; Lee PC; Paul S; Altorki NK
Ann Thorac Surg; 2011 Aug; 92(2):491-6; discussion 496-8. PubMed ID: 21704291
[TBL] [Abstract][Full Text] [Related]
37. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
38. Value of Lymphadenectomy in Patients Receiving Neoadjuvant Therapy for Esophageal Adenocarcinoma.
Raja S; Rice TW; Murthy SC; Ahmad U; Semple ME; Blackstone EH; Ishwaran H;
Ann Surg; 2021 Oct; 274(4):e320-e327. PubMed ID: 31850981
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
Samel S; Hofheinz R; Hundt A; Sturm J; Knoll MR; Wenz F; Queisser W; Post S
Onkologie; 2001 Jun; 24(3):278-82. PubMed ID: 11455222
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
